& Melinda Gates Foundation ... Net Worth

What's Foundation's mailing address?

's mailing address filed with the SEC is Seattle, WA 98102, USA.

Insiders trading at Vir Biotechnology Inc

Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I..., and Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.

What does Vir Biotechnology Inc do?

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

Vir Biotechnology Inc executives and stock owners

Vir Biotechnology Inc executives and other stock owners filed with the SEC include:

• George Scangos,
  President, Chief Executive Officer, Director
• Howard Horn,
  Chief Financial Officer, Secretary
• Herbert Virgin,
  Executive Vice President of Research and Chief Scientific Officer
• Vicki Sato,
  Independent Chairman of the Board
• Dr. Herbert W. Virgin IV, M.D., Ph.D.,
  Exec. VP of Research & Chief Scientific Officer
• Dr. Herbert W. Virgin IV,
  Exec. VP of Research & Chief Scientific Officer
• Dr. George A. Scangos Ph.D.,
  Pres, CEO & Director
• Dr. Ann M. Hanly Ph.D.,
  Exec. VP & Chief Technology Officer
• Phil Pang,
  Chief Medical Officer
• Dr. George A. Scangos,
  Pres, CEO & Director
• Dr. Phillip Pang M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Steven J. Rice,
  Chief Admin. Officer
• Saira Ramasastry,
  Independent Director
• Robert Perez,
  Independent Director
• Phillip Sharp,
  Independent Director
• Dr. Klaus Frueh,
  Co-Founder & Scientific Advisor
• Robert More,
  Independent Director
• Dipchand Nishar,
  Independent Director
• Robert Nelsen,
  Independent Director
• Elliott Sigal,
  Independent Director
• Janet Napolitano,
  Director
• Michael Kamarck,
  Chief Technology Officer
• Jay Parrish,
  Chief Business Officer
• Johanna Friedl-Naderer,
  Exec. VP & COO
• Irene Pleasure J.D., Ph.D.,
  Sr. VP & Gen. Counsel
• Heather Rowe Armstrong,
  VP of Investor Relations
• Dr. Aine M. Hanly Ph.D.,
  Chief Technology Officer
• Dr. Louis J. Picker M.D.,
  Co-Founder & Scientific Advisor
• Dr. Klaus Frueh Ph.D.,
  Co-Founder & Scientific Advisor
• Dr. Neera Dahiya Ravindran M.D., MBA,
  VP and Head of Investor Relations & Strategic Communications
• Dr. Louis J. Picker,
  Co-Founder & Scientific Advisor
• Dr. Lawrence Corey,
  Co-Founder & Scientific Advisor
• Permanent Fund Corp Alaska,
  
• & Melinda Gates Foundation ...,
  
• Johanna Friedl Naderer,
  EVP & Chief Operating Officer
• Steven J. Rice,
  Chief Administrative Officer
• Venture Partners Ix, Llcarc...,
  
• Endurance (Cayman) Ltd Sb I...,
  
• Dhabi Investment Authority ...,
  
• Holdings (Private) Ltd Full...,
  
• Program Ii (Co Invest Holdi...,
  
• Mark Eisner,
  EVP and Chief Medical Officer
• Klaus Frueh,
  Director
• Venture Partners Ix, Llcarc...,
  
• Kristina Burow,
  Director
• Jeffrey S. Hatfield,
  Director
• Norbert W Bischofberger,
  Director
• Ramy Farid,
  Director
• Sung Lee,
  EVP & Chief Financial Officer
• Ann M. Hanly,
  EVP & Chief Technology Officer
• Backer Marianne De,
  Chief Executive Officer